Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. develops and markets therapies for rare genetic diseases worldwide, offering approved biologics like Crysvita, Mepsevii, Dojolvi, and Evkeeza, while advancing Phase 3 gene‑therapy candidates such as UX143, UX111, and DTX401 through collaborations.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 1,294
HQ: Novato

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
RARE	Ultragenyx Pharmaceutical Inc. Cap: 2.2B	EQUITY	NMS	USD	US90400D1081	Active	📈